The MOG Project Applauds Hoffmann-LaRoche & Genentech Clinical Trial That May Signal First Approved Therapy for MOGAD
Results point to Enspryng® (Satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammation. WASHINGTON, DC, UNITED STATES, April 21, 2026 /EINPresswire.com/ -- The MOG Project is thrilled to share its excitement on the …